Build Your Own Vaccine Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Build Your Own Vaccine Facility
New modular bioprocessing technology could quicken the response to an outbreak of disease.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 14


Erik Greb
The recent outbreak of cholera in Haiti highlighted the urgent need, most acute in the developing world, for manufacturing capacity that can respond to pandemics rapidly. Modular technology under development by GE Healthcare (Waukesha, WI) and G-Con Manufacturing (College Station, TX) could provide a helpful solution.

The companies are combining GE Healthcare's single-use bioprocessing equipment and G-Con's cleanroom technology to create standard modular bioprocessing facilities (MBFs) that clients could fit with upstream or downstream utilities for their specific applications. If need be, users could refit MBFs with new equipment later without difficulty. Catarina Flyborg, general manager of bioprocess products at GE Healthcare, likens the technology to Legos that users can link to build manufacturing trains.

Each 18 25 ft unit could house as much as 2000 L of fermentation capacity. A set of air bearings underneath each MBF will ensure that personnel can physically move the units where they're needed. And, because each of the bioprocessing building blocks will be contained, clients will be able to install them in unclassified spaces.

The MBFs' modularity could help clients quickly set up a small-scale manufacturing facility in any location while requiring fewer capital expenses than building or renovating a facility would entail, says Flyborg. The new technology could make bioprocessing capacity more accessible than before and potentially help respond to emerging health crises quickly.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here